Skip to main content

Published 2022

Read in Norwegian

Publication details

Journal : BMJ Open , vol. 12 , 2022

International Standard Numbers :
Printed : 2044-6055
Electronic : 2044-6055

Publication type : Academic article

Contributors : Hjorth, Therese; Schadow, Alena; Revheim, Ingrid; Spielau, Ulrike; Thomassen, Lise Margrete; Meyer, Klara; Piotrowski, Katja; Rosendahl-Riise, Hanne; Rieder, Anne; Varela-Tomasco, Paula; Lysne, Vegard; Ballance, Simon; Koerner, Antje; Landberg, Rikard; Buyken, Anette E.; Dierkes, Jutta

Issue : 8

Research areas

Diet and health

Raw material knowledge

If you have questions about the publication, you may contact Nofima’s Chief Librarian.

Kjetil Aune
Chief Librarian
kjetil.aune@nofima.no

Summary

Introduction In 2012, the estimated global prevalence
of pre-diabetes
was 280 million, and the prevalence is
expected to rise to 400 million by 2030. Oat-based
foods
are a good source of beta-glucans,
which have been
shown to lower postprandial blood glucose. Studies to
evaluate the effectiveness of the long-term
intake of beta-glucan-
enriched
bread as part of a habitual diet among
individuals with pre-diabetes
are needed. Therefore, we
designed a multicentre intervention study in adults with
pre-diabetes
to investigate the effects of consumption
of an oat-derived
beta-glucan-
enriched
bread as part
of a normal diet on glycated haemoglobin (HbA1c) in
comparison to consumption of whole-grain
wheat bread.
Methods and analysis The CarbHealth trial is a multicentre
double-blind
randomised controlled 16-week
dietary
intervention trial in participants 40–70 years of age with a
body mass index of ≥27 kg/m2 and HbA1c of 35–50 mmol/
mol. The study is conducted at four universities located
in Norway, Sweden and Germany and uses intervention
breads specifically designed for the trial by Nofima AS. The
aim is to recruit 250 participants. The primary outcome is
the difference in HbA1c between the intervention and the
control groups. The main analysis will include intervention
group, study centre and baseline HbA1c as independent
variables in an analysis of covariance model.
Ethics and dissemination The study protocol was
approved by respective ethical authorities in participating
countries. The results of the study will be communicated
through publication in international scientific journals and
presentations at (inter)national conferences.
Trial registration number NCT04994327.

Contacts:

Topics associated with the publication